longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Major Insider Move at Globus Medical Sparks Investor Buzz

Tip Ranks
Jun 10, 2026 at 02:08 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Globus Medical (GMED) director David Davidar sold 25,000 shares worth $2.019 million on June 9, 2026, sparking investor interest. Despite this insider sale, GMED's stock was supported by strong Q1 results featuring double-digit revenue growth and raised EPS guidance. TipRanks' AI Analyst 'Spark' rates GMED as an Outperform, citing strong fundamentals and reasonable valuation (~18x earnings), though technical weakness and Nevro integration risks remain concerns.

New insider activity at Globus Medical ( (GMED) ) has taken place on June 9, 2026.

Globus Medical has seen notable insider activity as Director David Davidar disposed of 25,000 shares of the company’s stock in a transaction valued at $2,019,000. This insider sale may draw attention from investors watching ownership changes among the company’s leadership.

Globus Medical’s stock was influenced by its upbeat Q1 report, which showed strong double‑digit revenue growth, significant margin expansion, and raised EPS guidance driven by operating leverage and Nevro integration synergies. Some analysts adjusted views as they weighed this improving profitability, cash generation, and FDA‑backed product momentum against near‑term risks from Nevro’s revenue softness, higher SG&A, and a shift toward leasing enabling technologies that tempers top‑line visibility.

Spark’s Take on GMED Stock

According to Spark, TipRanks’ AI Analyst, GMED is a Outperform.

GMED scores well on fundamentals (strong growth, profitability, cash flow, and a very conservative balance sheet) and the latest earnings update was favorable with raised EPS guidance driven by margin expansion. The main drag is technical weakness (price below key moving averages with negative MACD), with secondary risks from Nevro integration and near-term revenue recognition headwinds in enabling technologies; valuation appears reasonable at ~18x earnings.

To see Spark’s full report on GMED stock,
click here.

More about Globus Medical

YTD Price Performance: -10.32%

Average Trading Volume: 1,409,182

Technical Sentiment Signal: Buy

Current Market Cap: $10.62B

Login to unlock1,139characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 9, 2026 at 04:53 AMUS to ban Canadian motorcycle, dairy, alcohol imports as trade war sizzles
  • Sep 8, 2026 at 12:14 PMAI-era DCI: Beyond the chip, compete as a network. Is there a China play?

Related Stocks

Globus Medical Inc

Globus Medical Inc

USGMED

-4.15%

Nevro

Nevro

USNVRO

LongbridgeAI